Abstract 11P
Background
Breast cancer is the second leading cause of cancer deaths in women worldwide. Early detection of breast cancer has been demonstrated to improve patients' treatment outcomes and survival. Liquid biopsy based on detecting DNA shed by breast tumors into the circulation, known as circulating tumor DNA (ctDNA), has emerged as a promising non-invasive approach. However, differentiating benign breast lumps from malignant tumors remains a challenge in current clinical practice, and inaccurate detection may result in unnecessary invasive procedures.
Methods
To address this challenge, we employed a multimodal analysis approach, namely SPOT-MAS (Screen for the Presence of Tumor by DNA Methylation and Size) to profile alterations in methylation and fragment length patterns of cell free DNA (cfDNA) from 133 breast cancer patients and 59 patients with benign breast lumps comprising cysts and fibroadenomas.
Results
We identified multiple distinct end motifs, differential methylation and fragment length patterns across 22 chromosomes, which were further exploited as input features to build machine learning models to discriminate early-stage breast cancer patients from patients with benign lesions. The models achieved an area under the curve of 0.87 (95% CI: 0.79 – 0.94) and a sensitivity of 64.1% at 90% specificity in detecting patients with malignant tumors.
Conclusions
Therefore, our findings demonstrated that cancer-specific methylation and fragmentomic patterns in plasma cfDNA could serve as novel biomarkers for accurately differentiating malignant breast cancer patients from those with benign lesions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Medical Genetics Institute and Gene Solutions Joint Stock Company, Vietnam.
Funding
Gene Solutions Joint Stock Company.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
442P - Negative impact on bone homeostasis in postmenopausal women with non-metastatic breast cancer during cytotoxic chemotherapy
Presenter: Yadav Nisha
Session: Poster Display
Resources:
Abstract
443P - Efficacy of vitamin D supplementation in overall survival of cancer patients: Systematic review and meta-analysis
Presenter: Visakha Irawan
Session: Poster Display
Resources:
Abstract
444P - Commencing a nurse led symptom and urgent review clinic (SURC) in a Victorian regional cancer centre
Presenter: Sue Bartlett
Session: Poster Display
Resources:
Abstract
445P - Self-reported symptom burden, quality of life and unmet need of symptom management in nasopharyngeal cancer survivors: A cross-sectional survey
Presenter: Jerry Ching
Session: Poster Display
Resources:
Abstract
446P - A single center experience of anamorelin in patients with non-small cell lung cancer
Presenter: Takanori Ito
Session: Poster Display
Resources:
Abstract
447P - Quality of life in patients with EGFR-mutated lung cancer receiving gefitinib vs gefitinib plus pemetrexed and carboplatin chemotherapy
Presenter: Nandini Menon
Session: Poster Display
Resources:
Abstract
448P - Association of clinicopathological characteristics and pro-inflammatory markers with reduced relative dose intensity in breast cancer chemotherapy
Presenter: Susanna Hutajulu
Session: Poster Display
Resources:
Abstract
449P - Psychometric validation of the MD Anderson symptom inventory head&neck module: Chinese version in nasopharyngeal cancer survivors
Presenter: Victor Tam
Session: Poster Display
Resources:
Abstract
450P - Retrospective study of anamorelin therapy for unresectable or recurrent pancreatic cancer with cancer cachexia
Presenter: Mao Okada
Session: Poster Display
Resources:
Abstract
451P - The real-world efficacy and safety of anamorelin hydrochloride for Japanese unresectable non-small cell lung cancer patients with cachexia
Presenter: Daisuke Arai
Session: Poster Display
Resources:
Abstract